[1]
|
滕媛, 李勇男, 楼松, 等. 抗Ⅹa活性在普通肝素抗凝监测中应用的研究进展[J]. 中国体外循环杂志, 2018, 16: 248-251. https://www.cnki.com.cn/Article/CJFDTOTAL-TWXH201804016.htm |
[2]
|
Kovács B, Bereczky Z, Selmeczi A, et al. Progressive chromogenic anti-factor Ⅹa assay and its use in the classification of antithrombin deficiencies[J]. Clin Chem Lab Med, 2014, 52: 1797-1806. http://www.ncbi.nlm.nih.gov/pubmed/24968404 |
[3]
|
David A, Trevor P, Jeffrey I, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J]. Chest, 2018, 141: e24S-e43S. http://www.scienceopen.com/document?vid=641686e2-5321-45a5-b505-07883517eee5 |
[4]
|
Khan F, Tritschler T, Kahn SR, et al. Venous thromboembolism[J]. Lancet, 2021, 398: 64-77. doi: 10.1016/S0140-6736(20)32658-1 |
[5]
|
Mulloy B, Hogwood J, Gray E, et al. Pharmacology of Heparin and Related Drugs[J]. Pharmacol Rev, 2016, 68: 76-141. http://www.ncbi.nlm.nih.gov/pubmed/26672027 |
[6]
|
Hannah L, Leah M, Majed A, et al. Updates in Anticoagulation Therapy Monitoring[J]. Blood, 1992, 79: 1-17. doi: 10.1182/blood.V79.1.1.1 |
[7]
|
Van Cott EM, Roberts AJ, Dager WE. Laboratory Monitor-ing of Parenteral Direct Thrombin Inhibitors[J]. Semin Thromb Hemost, 2017, 43: 270-276. doi: 10.1055/s-0036-1597297 |
[8]
|
Zhang N, Lou W, Ji F, et al. Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms[J]. Cancer Res Clin Oncol, 2016, 142: 1807-1816. doi: 10.1007/s00432-016-2131-6 |
[9]
|
Bates S, Weitz J, Johnston M, et al. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin[J]. Arch Intern Med, 2001, 161: 385-391. doi: 10.1001/archinte.161.3.385 |
[10]
|
Byun JH, Jang IS, Kim JW, et al. Establishing the heparin therapeutic range using aPTT and anti-Ⅹa measurements for monitoring unfractionated heparin therapy[J]. Blood Res, 2016, 51: 171-174. doi: 10.5045/br.2016.51.3.171 |
[11]
|
Kumano O, Akatsuchi K, Amiral J, et al. Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants[J]. Biomedicines, 2021, 9: 264-269. doi: 10.3390/biomedicines9030264 |
[12]
|
Vandiver JW, Vondracek TG. Antifactor Ⅹa levels versus activated partial thromboplastin time for monitoring unfractionated heparin[J]. Pharmacotherapy, 2012, 32: 546-558. doi: 10.1002/j.1875-9114.2011.01049.x |
[13]
|
Tan J, Ning T, Zhang W, et al. Heparin locks with low and high concentration in haemodialysis patients: A systematic review and meta-analysis[J]. Int J Nurs Pract, 2021, 27: e12907. doi: 10.1111/ijn.12907 |
[14]
|
Arachchillage D, Kamani F, Deplano S, et al. Should we abandon the aPTT for monitoring unfractionated heparin?[J]. Thromb Res, 2017, 8: 157-161. http://www.ncbi.nlm.nih.gov/pubmed/28759760 |
[15]
|
Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group[J]. Thromb Haemost, 1994, 71: 698-702. doi: 10.1055/s-0038-1642507 |
[16]
|
Bates S, Greer I, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141: e691S-e736S. doi: 10.1378/chest.11-2300 |
[17]
|
Wong SS, Lau WY, Ng ML, et al. Low-molecular weight heparin infusion as anticoagulation for haemodialysis[J]. Clin Kidney, 2016, 9: 630-635. doi: 10.1093/ckj/sfw049 |
[18]
|
Meyer MS, Geneviève C, Theodore ES, et al. Laboratory assessment of rivaroxaban: a review[J]. Thromb J, 2013, 11: 11. |